Astria Therapeutics, Inc. Income Statement
ATXS / Health Care|12 years of annual SEC 10-K data (FY2013-FY2024)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 12 fiscal years. All figures from audited SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 5.45 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | $500.0K | - | - | - | - |
| SG&A Expense | $34.5M | $25.7M | $19.2M | $14.8M | $11.8M | $8.8M | $9.3M | $8.9M | $10.1M | $8.6M | $6.0M | $4.1M |
| R&D Expense | $77.1M | $42.1M | $34.3M | $15.6M | $25.6M | $18.3M | $17.0M | $18.7M | $25.4M | $23.0M | $15.7M | $14.0M |
| Operating Income | -$111.6M | -$83.0M | -$53.5M | -$195.0M | -$37.4M | -$27.1M | -$26.4M | -$27.1M | -$35.6M | -$31.7M | -$21.7M | -$18.1M |
| Interest Expense | - | - | - | - | - | - | $100.0K | $462.0K | $837.0K | $978.0K | $206.0K | - |
| Net Income | -$94.3M | -$72.9M | -$51.8M | -$194.9M | -$37.3M | -$6.0M | -$25.9M | -$27.4M | -$36.1M | -$32.6M | -$21.9M | -$18.1M |
| EPS (Basic) | -$1.68 | -$2.42 | -$3.55 | -$24.58 | -$12.20 | - | - | - | - | - | - | - |
| EPS (Diluted) | -$1.68 | -$2.42 | -$3.55 | -$24.58 | -$12.20 | - | - | - | - | - | - | - |
| Shares Outstanding | 56.2M | 30.1M | 14.6M | 8.9M | 3.1M | 9.7M | 5.1M | 2.2M | 16.2M | 8.0M | 424.5K | 379.0K |